These presentations were recorded during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University in St. Louis: Cutting Edge Approaches in IBDManagement in 2022 held September 24, 2022, and supported in part by unrestricted educational grants from Boehringer Ingelheim, Bristol Myers Squibb, Ferring Pharmaceuticals, Janssen, and Pfizer, Inc.
This is a module of the session titled Management of Refractory UC originally presented during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University: Cutting Edge Approaches to IBD Management on Sept 24, 2022. Please also watch the other Perianal Crohn’s Disease Videos that preceded this Q&A.
The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
- Discuss studies to identify next generation IBD therapies
- Analyze the literature of updates in use of anti-tnf and anti-integrin therapies in IBD
- Describe the mechanism and rationale behind the development of targeted IL 12/23 and IL 23 inhibitors
- Evaluate current efficacy and safety data for approved IL 23 inhibitors for the management of IBD and Crohn's disease
- Identify the currently available janus kinase (JAK) inhibitors and S1P modulator for the treatment of moderate to severe ulcerative colitis
- Implement the safety monitoring required prior to and during treatment with JAK inhibitors and S1P modulators
Making a Difference: Patient-Centered Ulcerative Colitis Care in the Era of JAK Inhibitors and S1P Modulators0.75 credits
Alan C. Moss, MD, FACG, FEBG, AGAF, FRCPI
Sophie M. Balzora, MD
Latonia Ward, M.Min
Marla C Dubinsky, MD
Rishika Chugh, MD
Sara Horst, MD, MPH